FilingSEC EDGAR6-K
Alterity Therapeutics Confirms Phase 3 Design for ATH434 and Secures New Patent
· SEC accepted
StagePhase 3 Preparation
Filing content
The company confirmed the Phase 3 trial design for ATH434 with the FDA and secured a new U.S. composition of matter patent extending protection to 2045.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…